A newly designed airplane prototype does away with noisy propellers and turbines.
Instead, it’s powered by ionic wind: charged molecules, or ions, flowing in one direction and pushing the plane in the other. That setup makes the aircraft nearly silent. Such stealth planes could be useful for monitoring environmental conditions or capturing aerial imagery without disturbing natural habitats below.
The aircraft is the first of its kind to be propelled in this way, researchers report in the Nov. 22 Nature. In 10 indoor test flights the small plane, which weighs about as much as a Chihuahua, traveled 40 to 45 meters for almost 10 seconds at a steady height, even gaining about half a meter of altitude over the course of a flight. Most planes rely on spinning parts to move forward. In some, an engine turns a propeller that pushes the plane forward. Or a turbine sucks in air with a spinning fan, and then shoots out jets of gas that propel the plane forward.
Ionic wind is instead generated by a high-voltage electric field around a positively charged wire, called an emitter. The electricity, often supplied by batteries, makes electrons in the air collide with atoms and molecules, which then release other electrons. That creates a swarm of positively charged air molecules around the emitter, which are drawn to a negatively charged wire. The movement of molecules between the two wires, the ionic wind, can push a plane forward. The current design uses four sets of these wires. Moving ions have helped other things to fly through the air, such as tiny airborne robots. But conventional wisdom said that using the approach to move something through the air as big as an airplane wasn’t possible, because adding enough battery power to propel a plane this way would make it too heavy to stay aloft. (The ion thrusters that propel spacecraft through the vacuum of space work in a very different way and aren’t functional in air.) Attempts to build ion-propelled aircraft in the 1960s weren’t very successful. MIT aeronautics researcher Steven Barrett thought differently. With the right aircraft design and light enough batteries, flight might be possible, his initial calculations suggested. So he and his team used mathematical equations to optimize various features of the airplane — its shape, materials, power supply — and to predict how each version would fly. Then the researchers built prototypes of promising designs and tested the planes at the MIT indoor track, launching them via a bungee system. “The models and the reality of construction don’t always match up perfectly,” Barrett says, so finding the right design took a lot of tries. But in the new study, he and his collaborators report success: 10 flights of the aircraft, which has a 5-meter wingspan and weighs just under 2.5 kilograms.
Barrett’s team isn’t the only one who thought the ionic wind method might take off. Based on calculations done in his lab, “we were confident that this could be done,” says Franck Plouraboue of the Toulouse Fluid Mechanics Institute in France, who wasn’t part of the research. “Here they’ve done it — which is fantastic!”
It’s an example of distributed electric propulsion, says Plouraboue — spreading out the thrust-generating parts of the plane, instead of having one centralized source. That’s a hot area for aircraft research right now. NASA’s X-57 Maxwell plane, for example, bears 14 battery-operated motors along its wings. Increasing the number of propellers makes the plane go farther on the same amount of energy, says Plouraboue, but also increases the drag. With ionic wind propulsion, increasing the number of wires doesn’t increase drag very much.
The plane still needs some upgrades before it’s ready for the real world: Its longest flight was only 12 seconds. And while the aircraft can maintain steady flight for a short time once launched, it can’t actually get off the ground using ionic wind.
Even with improvements, ion-propelled aircraft won’t find their niche as passenger planes, predicts Daniel Drew, an aerodynamics researcher at the University of California, Berkeley, who was not involved in the work. (Drew has designed miniature flying bots that fly using ionic propulsion.) It’s probably not feasible to scale up to something the size of a 747 — there are efficiency trade-offs as planes get bigger, he says. But down the road, the approach might be useful for small, uncrewed planes or drones.
Devices that eavesdrop on neural activity can help paralyzed people command computer tablets to stream music, text friends, check the weather or surf the internet.
Three people with paralysis below the neck were able to navigate off-the-shelf computer tablets using an electrode array system called BrainGate2. The results, published November 21 in PLOS One, are the latest to show that neural signals can be harnessed to directly allow movement (SN: 6/16/12, p. 5).
The two men and one woman had electrode grids implanted over part of the motor cortex, an area of the brain that helps control movement. The brain implants picked up neural activity indicating that the participants were thinking about moving a cursor. Those patterns were then sent to a virtual mouse that was wirelessly paired to the tablet. Using nothing more than their intentions to move a cursor, the three participants performed seven common digital tasks, including web browsing and sending e-mail. One participant looked up orchid care, ordered groceries online and played a digital piano. “The tablet became second nature to me, very intuitive,” she told the researchers when asked about her experience, according to the study.
Another participant enjoyed texting friends, “especially because I could interject some humor,” he told the scientists. The system even allowed two of the participants to chat with each other in real time.
For the study, the researchers used tablets with standard settings, without installing any shortcuts or features to make typing or navigation easier.
SAN DIEGO — Getting goose bumps doesn’t just make hairs stand on end; it may also help hair grow.
Nerves and muscles that raise goose bumps also stimulate stem cells in the skin to make hair follicles and grow hair. Ya-Chieh Hsu, a stem cell researcher at Harvard University, reported the unpublished findings December 9 at the joint meeting of the American Society for Cell Biology and the European Molecular Biology Organization. Getting goose bumps when it’s cold may encourage animals’ fur to grow thicker, Hsu said. Nerves that are part of the sympathetic nervous system — which controls pupil dilation, heart rate and other automatic processes — nestle next to stem cells that will create hair follicles, Hsu and her colleagues found. Usually nerves are wrapped in a protective coating called myelin, like electrical wire sheathed in plastic. But Hsu’s group found that the nerves’ ends were naked where they meet hair follicle stem cells, like wires stripped at the tips to make contacts with electrical nodes.
The nerves secrete the hormone norepinephrine. That hormone is necessary for hair growth, the researchers found. Those findings might help explain why hair loss is a side effect of drugs known as beta-blockers, which interfere with norepinephrine’s action.
Sympathetic nerves next to hair follicles are also wrapped around tiny arrector pili muscles, which contract to make hair cells stand on end, causing goose bumps. Mice with mutations that prevented the muscles from growing also lacked the sympathetic nerves and didn’t grow hair normally. Men with male pattern baldness also lack arrector pili muscles in their scalps, Hsu said, suggesting that sympathetic nerves and goose bump–raising muscles may also be important in that type of baldness. Restoring the nerves and muscles may lead to new hair growth, she said.
From tales about whales to enthralling scientific histories and the memoir of a frustrated astrophysicist, 2018 was a banner year for science books. Here are Science News’ picks for the titles that should be on any science lover’s bookshelf. Find detailed reviews of many of these books in the links below and in our Editor’s Pick: Favorite books of 2018.
The Truth About Animals Lucy Cooke
A zoologist debunks myths about bats, pandas, Adélie penguins and many other misunderstood creatures, recounting surprising stories from the animal kingdom (SN: 4/14/18, p. 26). Basic Books, $28
Spying On Whales Nick Pyenson
In this captivating look at whales, a paleontologist dives into the animals’ past, exploring how some of Earth’s most intelligent species came to be, and their uncertain future (SN: 7/7/18, p. 29). Viking, $27
Eager Ben Goldfarb
Some people see beavers as pests. But a science writer explains how the dam-building rodents are actually vital ecosystem engineers that can create or expand habitats that benefit the entire wildlife community (SN: 8/4/18, p. 28). Chelsea Green Publishing, $24.95
The Rise and Fall of the Dinosaurs Steve Brusatte
In this memoir, a paleontologist blends experiences from his career with evolutionary science to take readers on an engrossing journey through time, from the beginnings of the dinosaurs to their ultimate extinction. William Morrow, $29.99
The Big Ones Lucy Jones
A seismologist examines past catastrophic natural disasters, including volcanic eruptions, earthquakes and floods, and their impact on culture, politics and society (SN: 3/31/18, p. 26). With the past as a guide, the author warns readers to be prepared for when the next disaster strikes. Doubleday, $26.95
Losing the Nobel Prize Brian Keating
An astrophysicist’s dream of winning a Nobel Prize turned to dust after a promising experiment failed to find the first definitive evidence of cosmic inflation. The experience revealed how the prize can hamper scientific progress (SN: 4/14/18, p. 27). W.W. Norton & Co., $27.95
The Poisoned City Anna Clark
Weaving together history, science and reporting, a journalist explores the public health crisis that began in Flint, Mich., when lead started leaching into residents’ drinking water (SN: 7/21/18, p. 28). Metropolitan Books, $30
The Poison Squad Deborah Blum
A Pulitzer Prize–winning journalist tells the story of a government chemist at the turn of the 20th century and his mission to make food safe in the United States. Penguin Press, $28
Aroused Randi Hutter Epstein
The history of endocrinology makes for a strange and fascinating read, from the scientists who discovered the effects of hormones to the people whose lives have been irrevocably changed by these powerful substances (SN: 7/7/18, p. 28). W.W. Norton & Co., $26.95
Nine Pints Rose George
Blood, the feared as well as revered substance that flows throughout the human body, has a rich historical and scientific past (SN: 10/27/18, p. 28). Metropolitan Books, $30
She Has Her Mother’s Laugh Carl Zimmer
This comprehensive history recounts how researchers have come to understand genetic inheritance. Looking to the future, the author considers risks of gene manipulation (SN: 6/9/18, p. 29). Dutton, $30
Genetics in the Madhouse Theodore M. Porter
Using archival records, a science historian traces the origins of the study of human heredity to insane asylums in the 1800s (SN: 7/7/18, p. 29). Princeton Univ., $35
The Tangled Tree David Quammen
In chronicling the lives of researchers who made important advances in molecular biology and genetics, this book shows how recent findings shake up our understanding of evolution and the tree of life. Simon & Schuster, $30
An orbital oopsie has led to new proof of Albert Einstein’s physics prowess.
In 2014, two satellites intended for Europe’s Galileo network, the equivalent of the United States’ GPS network, were placed into orbit incorrectly, causing them to travel around Earth in ellipses rather than circles. That wasn’t ideal for the satellites’ originally intended navigational use, but scientists realized the wayward satellites were perfect for another purpose: testing Einstein’s theory of gravity, the general theory of relativity.
According to general relativity, gravity affects not just space, but also time. The deeper within a gravitational field you are, the slower time passes (SN: 10/17/15, p. 16). So a clock at a higher altitude will tick faster than one closer to Earth’s surface, where Earth’s gravity is stronger. The satellites’ orbital mishap allowed the most precise test yet of this effect, known as gravitational redshift, two teams of scientists report in a pair of papers in the Dec. 7 Physical Review Letters.
As the two misplaced satellites move in their elliptical orbits, their distance from Earth periodically increases and decreases by about 8,500 kilometers. Using the precise atomic clocks on the satellites, the scientists studied how that altitude change affected the flow of time. The clocks sped up and slowed down by tiny fractions of a second as expected, agreeing with the predictions of general relativity within a few thousandths of a percent, the teams report.
SEATTLE — The next generation exoplanet hunter is coming into its own. NASA’s Transiting Exoplanet Survey Satellite, or TESS, has already found eight confirmed planets in its first four months of observing — and some are unlike anything astronomers have seen before.
“The torrent of data is starting to flow already,” TESS principal investigator George Ricker of MIT said January 7 in a news conference at a meeting of the American Astronomical Society.
TESS launched in April and began science observations in July (SN: 5/12/18, p. 7). It was designed to be a follow-up to the prolific Kepler space telescope, which went dark in October after almost a decade of observing (SN Online: 10/30/18). Like Kepler, TESS searches for planets by watching for dips in starlight as planets cross, or transit, in front of their stars. Unlike Kepler, which stared unblinkingly at a single patch of sky for years, TESS scans a new segment of sky every month. Over two years, TESS will cover the entire 360 degrees of sky visible from Earth’s orbit.
In the first four segments, TESS has already spotted eight confirmed planets and more than 320 unconfirmed candidates, said Xu Chelsea Huang of MIT. And several of them are downright strange. Take the third-found planet, HD 21749b. Only 52 light-years away, it has the lowest temperature known for a planet orbiting a bright, nearby star, astronomers reported at the meeting and in a paper posted at arXiv.org on January 1. That makes it a great candidate for follow-up observations with future telescopes like the James Webb Space Telescope, scheduled to launch in 2021. Webb will use starlight filtering through the atmospheres of planets like this one to measure those atmospheres’ properties and search for signs of life (SN: 4/30/16, p. 32).
“If we want to study atmospheres of cool planets, this is the one to start with,” Huang said.
“Cool” is a relative term. This particular planet is still probably too hot and gassy to host life. Its orbit takes 36 Earth days, the longest known orbital period for planets transiting bright stars within 100 light-years of the sun.
That leaves it at a distance from the star that should heat the planet’s surface to about 150° Celsius, too hot for liquid water. And at 2.84 times Earth’s size and 23.2 times Earth’s mass, its density suggests it must have a thick atmosphere, unlike Earth’s life-friendly one.
But it’s still worth checking out, says astronomer Diana Dragomir of MIT, a member of the TESS team. Despite its heat, this planet is “tepid” compared with most of the scorched worlds whose atmospheres astronomers can probe right now, she says, so closer to an Earthlike system. Smaller, cooler, more Earthlike worlds are few and far between, and may not orbit such bright stars.
Finding more longer-period planets “helps you explore the diversity of planets that are out there,” says astronomer Paul Dalba of the University of California, Riverside, who studies exoplanet atmospheres but was not involved in the TESS discovery. Because TESS spends such a short stretch of time looking at each segment of the sky, astronomers expect most of its planets to have shorter years than an Earth month. “The fact that we’re already getting one that’s longer period I think is just really exciting, showing that TESS isn’t just for the shortest-period exoplanets.” The other planets in TESS’s first haul are equally exotic. TESS’s first find, Pi Mensae c, was reported in September ( SN Online: 9/18/18 ). The planet orbits its star every 6.27 days, and is about 2.14 times Earth’s size and 4.8 times Earth’s mass, giving it a density similar to pure water. The weirdest thing about that super-Earth is the company it keeps, Huang said. Previous observations showed that the star Pi Mensae also has a planet 10 times the mass of Jupiter that orbits every 5.7 years. That planet, Pi Mensae b, revolves on a wildly eccentric orbit, swinging between the distance of Earth and the distance of Jupiter from its star.
“This is the most extreme system we know of that has this type of architecture,” Huang said.
Theories of how planets develop such wonky orbits suggest that this super-Jupiter should have booted Pi Mensae c out of the system (SN: 5/12/18, p. 28). “We are really surprised that the inner super-Earth actually survived that disruptive event,” Huang said. “It’s a mystery we really want to understand.”
The second planet found by TESS, LHS 3844b, has a radius just 1.3 times Earth’s. But it swings around its star every 11 hours, giving it a surface temperature of about 540° C, Huang said. “It’s likely a lava world.”
TESS has completed about one-twelfth of its first sky survey, but Ricker is already writing proposals to extend its initial two-year mission. TESS’s orbit is held stable by the moon’s gravity, so it doesn’t need to spend any fuel to stay put. The fuel on board, used to change the direction the telescope points, is enough to last for 300 years.
“The orbit itself was designed to be extremely stable on timescales of decades to centuries,” Ricker said. “TESS is really going to be an important part of our astronomical efforts for the next decade and for more to come.”
Editor’s note: This story was updated January 29, 2019, to correct the description of the planet LHS 3844b’s orbit. It orbits a star, not a planet.
Poop contains a lot of valuable scientific information. Researchers can monitor microbes, track enzyme activity or hunt for DNA to gather clues about overall health.
There’s so much one can learn from the waste product that microbiologist Aadra Bhatt at the University of North Carolina at Chapel Hill decided there should be a word for that research — something in the same vein as “in vivo” (research done in living animals) and “in vitro” (research done in a petri dish).
After some linguistic digging, she and two colleagues settled on “in fimo.” The term comes from fimus, one of several Latin words for manure or excrement. Their choice won out over the more obvious option of “in feces” because the word feces doesn’t have the same rich scatological legacy — originally it referred to the dregs in a wine cask, Bhatt says.
She and her colleagues, while already using in fimo at meetings and seminars, published their argument online December 13 in Gastroenterology. Compared with the laborious process of pulling together a scientific paper, coming up with this term was “delightful — and it wasn’t particularly drawn out,” Bhatt says. She hopes the word catches on and gains a place in the lexicon for poopetuity.
SEATTLE — Astronomers have spotted a second repeating fast radio burst, and it looks a lot like the first. The existence of a second repeating burst suggests there could be many more of the mysterious signals in the cosmos.
The burst, called FRB 180814.J0422+73, is one of 13 newly discovered fast radio bursts, or FRBs — brief, bright signals of radio energy that come from distant galaxies. The FRBs were detected over a few weeks last year by the Canadian Hydrogen Intensity Mapping Experiment, or CHIME, in British Columbia. Astronomers reported the discoveries at a meeting of the American Astronomical Society on January 7 and in the Jan. 9 Nature. Most such bursts erupt once, last for a few milliseconds, and are never seen again. So astronomers have puzzled over what causes them for years (SN: 8/9/14, p. 22).
“If you have something that flashes for a millisecond in the sky, and there’s nothing that happens for many years, it’s really hard to study,” says astronomer Shriharsh Tendulkar of McGill University in Montreal, a member of the CHIME team.
But then in 2016, astronomers discovered the first repeating FRB when they realized that a series of bursts all came from a single source, called FRB 121102 (SN: 4/2/16, p. 12). Astronomers tracked the signal to its host galaxy (SN: 2/4/17, p. 10) and determined it was coming from an extremely magnetic environment, such as the region surrounding a black hole (SN: 2/3/18, p. 6). Researchers didn’t know if FRB 121102’s repeating signal was unique. Of the more than 60 FRBs detected, no other was known to repeat — until now. Having spotted a second one, scientists are searching for more.
“Imagine you saw a unicorn,” Tendulkar says. “Then suddenly you discover another one. You know now there is a population of these. There is hope for discovering a lot more.” The CHIME team detected the first of the repeating FRB signals on August 14, with four more coming over the next two months from the same spot on the sky. It wasn’t until the third burst, on September 17, that the team realized they might have a repeater, Tendulkar says.
“Somebody pointed out, hey look, these three bursts seem to have the same properties,” he says. “Everybody got really excited.”
Calculations show that the new repeater is about 1.6 billion light-years away. The CHIME team also saw an odd similarity between the two known repeating bursts. Most FRBs are just a sharp blip, akin to a single note being played on a trumpet. But some of the individual bursts in both repeaters were made up of multiple sub-bursts that descended in frequency, like the “wah wah wah wah” of a sad trombone.
“We’ve seen this in 121102, and we can’t explain it,” says astronomer Emily Petroff of ASTRON, the Netherlands Institute of Radio Astronomy, who was not involved in the new work. “Up until now we’ve only had the one repeater, and it’s given us more questions than answers.” But the fact that both repeaters behave similarly could suggest they have similar origins, she says.
Astronomers may have already caught a third repeating burst, too. FRB 110523, discovered in 2015, has some similar features to the first known repeating FRB, so it was worth checking to see if it also repeats, said astronomer Allison McCarthy of the University of Alabama in Tuscaloosa.
Together with Andrew Seymour of the Green Bank Observatory in West Virginia, McCarthy analyzed more than 41 hours of observations of FRB 110523 taken at the Arecibo Observatory in Puerto Rico. They found one potential repeat burst, McCarthy reported January 9 in a poster at the AAS meeting, but they’re not declaring victory just yet. “It wasn’t strong enough for us to be very sure we had detected one,” McCarthy said, adding that they’re about 60 percent certain. “But it’s still a promising candidate.”
Astronomers’ theories for what causes FRBs are almost as numerous as known FRBs themselves. At one point, astronomers even considered the idea that FRBs could be signals from intelligent aliens. But it’s unclear if the repeating bursts and single bursts both come from the same kinds of sources, or even if one-offs might also repeat if watched for long enough.
“It’s the wild, wild west out there,” Tendulkar says. “We have tantalizing clues, but it’s hard to make definitive conclusions.”
CHIME is likely to catch a lot more of these fast radio bursts. The telescope was still being tested when it caught the 13 new ones, so was not operating at peak performance. “They just barely turned on the telescope,” Petroff says, “and they’re already finding things.”
SAN FRANCISCO — Seizures during sleep can scramble memories — a preliminary finding that may help explain why people with epilepsy sometimes have trouble remembering.
The sleeping brain normally rehashes newly learned material, a nocturnal rehearsal that strengthens those memories. Neuroscientist Jessica Creery and her colleagues forced this rehearsal by playing certain sounds while nine people with epilepsy learned where on a screen certain pictures of common objects were located. Then, while the subjects later slept, the researchers played the sounds to call up some of the associated memories.
This sneaky method of strengthening memories, called targeted memory reactivation, worked as expected for five people who didn’t have seizures during the process. When these people woke up, they remembered the picture locations reactivated by a tone better than those that weren’t reactivated during sleep, said Creery, of Northwestern University in Evanston, Ill. She presented the research March 25 at the annual meeting of the Cognitive Neuroscience Society.
The opposite was true, however, for four people who had mild seizures, detected only by electrodes implanted deep in the brain, while they slept. For these people, memory reactivation during sleep actually worsened memories, making the reactivated memories weaker than the memories that weren’t reactivated during sleep. The combination of seizures and memory reactivation “seems like it’s actually scrambling the memory,” Creery says, a finding that suggests that seizures somehow accelerate forgetting.
A few months back, a new storefront appeared in my small Oregon town. Its shelves were packed with tinctures, jars of salve, coffee beans, bath bombs — even beard oil. This motley collection shared a single star ingredient: CBD.
Produced by the cannabis plant, CBD is the straitlaced cousin of marijuana’s more famous component — the THC that delivers a mind-swirling high. CBD, or cannabidiol, has no such intoxicating effects on the mind. Yet the molecule has captured people’s attention in a profound way, sold as a remedy for pain, anxiety, insomnia and other ailments — all without the high.
That neighborhood shop, CBD Scientific, is far from alone in its efforts to sell people on the benefits of CBD, which is found in both marijuana and hemp, two versions of the Cannabis sativa plant. CBD is popping up in products in pet stores, coffee shops and the health and beauty sections of mainstream grocery stores. It’s even being brewed into beer. I left the shop with a $5 bottle of water infused with “5,000,000 nanograms” of CBD.
So far, messages of CBD’s purported health benefits come from people trying to sell CBD products — not from scientists, says Margaret Haney, a neurobiologist who directs the Marijuana Research Laboratory at Columbia University. A gaping chasm separates the surging CBD market and the scientific evidence backing it. While there are reasons to be excited about CBD, the science just isn’t there yet, Haney says. Scientists still don’t know all of the targets CBD hits in the human body, nor what effects it may have, if any. With the exception of tests in people with rare forms of epilepsy, large studies that compare CBD with placebos in people are rare. Much of the existing research was done with cells in the lab or in lab animals, with results that don’t necessarily translate to people.
And there’s always the chance that for some people, CBD’s magic is made not by the compound itself but by a powerful placebo effect; people who expect good outcomes are more likely to see benefits.
Researchers are stepping into the void, lured by promising early data. Small trials are under way looking at the effect of CBD on anxiety, pain, opioid addiction, depression and other health problems. National Institutes of Health funding for CBD studies went from zero in 2014 to an estimated $16 million in 2018. “We’re very interested in CBD,” says Susan Weiss, director of the Division of Extramural Research at the National Institute on Drug Abuse in Bethesda, Md. Still, she urges caution to people eager to try CBD. Because of lax oversight, there’s no telling what’s inside many of those tinctures, oils, rubs and foods for sale online and in stores. “A lot of the products that people are taking may not be what they think,” she says.
Despite the risks and warnings, it seems safe to say that the collective fascination with CBD isn’t going to wear off anytime soon. “People think it’s great for everything,” says cognitive neuroscientist Kent Hutchison of the University of Colorado Boulder. That can’t possibly be true, he says. “But I do think it’s going to be great for some things. We just need to figure out what those things are.”
Mystery molecule Each morning, Samantha Montanaro of Portland, Ore., drops a CBD tincture under her tongue. “I’m kind of testing out my own body with this,” she says. “I’m finding that it really helps with anxiety and stress.”
Montanaro isn’t alone; CBD testimonials are increasingly easy to find. In 2016, Montanaro, now 35, cofounded Tokeativity, a global cannabis community for women. Back then, “CBD wasn’t even a thing,” she says. But the first sparks of the CBD movement caught fire fast. “It’s been pretty crazy to watch how things have evolved,” she says. Some bullish analysts predict that the CBD market in the United States will balloon from hundreds of millions of dollars in 2018 to almost $20 billion by 2022.
Ziva Cooper directs UCLA’s Cannabis Research Initiative and fields a lot of questions about CBD. Her answers invariably disappoint. “When I tell [people] we don’t have very much evidence in people, they’re actually surprised,” she says. When it comes to CBD’s benefits, “there’s actually very little out there to hang our hats on.”
The one exception is for rare forms of childhood epilepsy. Neurologist Elizabeth Thiele of Massachusetts General Hospital in Boston had a young patient who was having over 100 seizures a day. After other treatments had failed, the boy’s parents began searching for a source of CBD oil, which they desperately wanted to try after learning about promising early results in animals. The family flew to England, so the boy could try the CBD formulation made by GW Pharmaceuticals. The child’s results, Thiele says, were remarkable. After a week of CBD, his daily seizures had fallen to single digits. That result ultimately led to clinical trials, one of which included 171 people, mostly children, with Lennox-Gastaut syndrome, a rare and severe seizure disorder. In addition to their normal medication, half of the participants got doses of CBD that were rigorously tested and standardized by the drug’s maker. The other half received their regular treatment plus a placebo. After 14 weeks, the people taking CBD saw a median drop in monthly seizure frequency of about 44 percent; seizures in people who took the placebo dropped almost 22 percent. Thiele and her colleagues published those results in March 2018 in the Lancet.
Side effects were manageable, the researchers found. Diarrhea, sleepiness, poor appetite and vomiting were more likely to occur in the people who took CBD than in those who got the placebo. Along with results from several other trials, those data were strong enough to prompt the U.S. Food and Drug Administration to approve the CBD drug, called Epidiolex, last June. Despite rigorous testing of Epidiolex, big gaps in knowledge on how the drug works in epilepsy remain. Researchers don’t know how CBD tames seizures. Because the molecule comes from cannabis, the early assumption was that CBD latches onto the same chemical receptors that THC connects to, one primarily in the brain and one mainly on immune cells. It turns out, however, that CBD doesn’t seem to hit either of those receptors.
Instead, studies in rats and mice point to two different targets. One, called TRPV1, is known to play a role in pain sensation and maybe epilepsy, too. The other, called GPR55, might change the activity level of nerve cells in the brain, a feat that may be behind CBD’s antiseizure power.
Scientists also don’t know whether CBD keeps working year after year. For some of Thiele’s patients, CBD seems to still be effective after five years of taking the drug, even allowing them to taper off some of their other medications, she says. But data from 92 other patients, presented in December at the American Epilepsy Society’s annual meeting, suggest that CBD’s benefits can start to fade after about seven months on the drug. About a third of the people in the study needed a dose increase after their CBD doses became less effective, researchers from Tel Aviv Sourasky Medical Center reported.
Research on CBD and other ailments lags way behind the epilepsy work. Early experiments, mostly on lab animals but some in small numbers of people, suggest that CBD might fight anxiety, ease schizophrenia symptoms and address pain.
One example: Healthy men who took CBD before a stressful public speaking task were calmer than those who took a placebo, researchers reported in October in the Brazilian Journal of Psychiatry. But only the 15 men who received doses of 300 milligrams were more relaxed. The 27 who took less or more CBD didn’t see benefits. Other types of studies with people, and studies of mice and rats, have turned up antianxiety effects, too. But most of these studies looked at single doses of CBD, not consistent use.
Early evidence of CBD’s promise against schizophrenia comes from a trial of 88 people with the disorder. After six weeks, people who had received a big daily dose of CBD (1,000 milligrams a day) in addition to their normal medication had more improvements in certain symptoms when compared with people who received a placebo. Those results hint that CBD might be a new type of drug for schizophrenia, researchers wrote in March 2018 in the American Journal of Psychiatry.
Studies in lab animals suggest that CBD may help relieve chronic pain. A study appearing in 2017 in Pain found that CBD could block osteoarthritis pain and nerve damage in rats. Hard data for humans are harder to find, but anecdotes abound. Pain clinician Kimberly Mauer of Oregon Health & Science University in Portland and colleagues at the OHSU Comprehensive Pain Center have seen an uptick in patients who say they’re taking CBD. Their experiences are mixed, she says: “About half the patients say they get some benefit, and about half say they didn’t notice anything.”
No easy access To answer the many outstanding questions about CBD’s effects, scientists need access to the compound. But a complex web of U.S. regulations makes that difficult. CBD is subject to rules from both the FDA and the U.S. Drug Enforcement Administration. CBD produced by the marijuana plant remains on the DEA’s list of the most restrictive class of drugs, Schedule 1, alongside LSD, ecstasy and other drugs deemed to have no accepted medical use and high potential for abuse. Access restrictions on industrial hemp, and by extension, the CBD that comes from hemp, were eliminated in the 2018 Farm Bill, signed into law in December. However, regardless of its provenance, CBD is still subject to FDA regulations, as well as any regulations imposed by states. “As easy as it’s gotten for the average person to go legally to buy recreational marijuana and consume it in many states, it’s gotten harder for scientists,” says Haney at Columbia. One of the few approved sources of CBD is a government-sanctioned cannabis facility at the University of Mississippi in Oxford. After she gets the CBD she needs for her studies, Haney is required to meticulously account for every milligram. “I have a gun safe in a locked room that I get into with my fingerprints to store both cannabidiol and marijuana.”
With those restrictions, many scientists just can’t do the studies they want, Hutchison says. “The whole thing is a little bit crazy. People can sell it everywhere, but it’s very difficult for scientists to study its effects in humans.”
Hutchison and colleagues have figured out a legal work-around that doesn’t require researchers to obtain supplies of CBD. The team is avoiding the government-grown cannabis, which can be quite different from the products in circulation, by testing the effects of the cannabis products that people are actually using. To do this, the researchers created a mobile pharmacology lab they call the CannaVan. The tricked-out Dodge contains equipment to study people after they’ve taken a product containing CBD (or THC) that they bought themselves. The researchers are currently collecting data on CBD’s effects on anxiety and pain. Buyer beware FDA rules say that CBD cannot be legally added to food and sold across state lines, sold as a dietary supplement or marketed with claims of treating diseases. But aside from sending some warning letters, the FDA has, so far, let the marketplace run uninhibited. (Some local health authorities, however, are beginning to flex their might, warning restaurants in New York City, for instance, to take CBD off the menu.)
Overall, no one really knows what’s inside the bottles, rubs and coffees for sale. A study published in 2017 in JAMA gives a sense of the problem. Researchers ordered and tested 84 products sold online in 2016 as CBD-containing products. Of those, only 26 were labeled accurately (containing CBD within 10 percent of the claimed amount); 36 of the products had more CBD than their labels said; and 22 products had less. The researchers also found THC in 18 of the 84 samples. Sophie Cloyd is a 30-year-old manager for the CBD company Ablis of Bend, Ore. She is also pregnant. I met her recently at a ski lodge, where she was offering beverage tastes and describing tinctures, oils and lotions. CBD, she says, has helped her manage this pregnancy, her second. She was prescribed the anti-nausea drug Zofran early in her pregnancy, but “the research on Zofran scared me more than the lack of research on CBD,” she says.
Ablis, which makes CBD-infused fizzy drinks and other products, currently gets purified CBD from Colorado, Cloyd says. When the CBD arrives, the company sends it to an independent lab to confirm that it has the right amount of CBD, no pesticides and no THC. But not all CBD sellers test their products.
An unexpected THC dose might not be enough to get a user high, but it could still be a problem, as news reports have begun to point out. To ease his pain from psoriatic arthritis, a school bus driver in Beaverton, Ore., had been taking a daily dose of CBD oil. In early 2018, he failed a periodic drug test with high THC levels, which caused him to lose his job, Portland news channel KATU reported. Even seemingly small amounts of THC can build up in the body with repeated use.
A product might contain even worse surprises. Between December 2017 and January 2018, for example, 52 people fell ill in Utah, with symptoms such as hallucinations, vomiting and seizures, after taking what they thought was CBD. It turned out that the products, many labeled “Yolo CBD oil,” contained a synthetic cannabinoid, and it had poisoned them.
Even if product labels were always accurate, people have no idea of the correct dose of CBD (assuming the right dose would be effective). “You see it marketed in doses like 10 milligrams,” Hutchison says. “Well, 10 milligrams probably does nothing.” For comparison, people who participated in one Epidiolex study took 20 milligrams per kilogram of body weight. To reach that daily dose, I’d need to chug 254 bottles of that 5 million nanogram CBD water I bought — at a cost of $1,270.
Haney makes the same point: “You’re not getting anything resembling an effective dose when you get CBD added to your coffee, or you buy a mint with a little bit of CBD in it,” she says.
There’s even less known about CBD products that you rub on your skin. Scientists don’t know that CBD in creams, oils and ointments actually makes it into the body. “I’m not convinced that anything you’re rubbing on your body with CBD is even getting through,” Haney says. At its heart, the trouble is that most CBD use isn’t backed up by science, Haney says. “I am not against CBD,” she says. In fact, she is about to start a study looking at CBD to treat nerve pain due to chemotherapy in cancer patients. “But I don’t like marketers determining what it’s good for and what it’s not.”
Hype run amok isn’t anything new, says Mauer, the OHSU pain doctor. Consumers try lots of things before the science is definitive — keto diets, for instance, or vitamin D supplements (SN: 2/2/19, p. 16). And even if it turns out that the chemical doesn’t work, the placebo effect might be enough to help reduce symptoms.
So far, the science on CBD isn’t mature enough to weigh in, one way or another. But judging by the number of studies and clinical trials under way, this nascent research field is growing up fast, seeking to quickly fill the space between the science and what people want to know.
This research boom heartens Montanaro. Her message to the scientific community: “I would encourage curiosity,” she says. “I’m not a doctor, and I’m not a scientist, but I certainly know my own body,” and she says that CBD helps her. From her perspective, science has got some catching up to do.
This story appears in the March 30, 2019 issue of Science News with the headline, “The Allure of CBD: People seek health benefits despite lack of evidence.”
